董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James Martin | 男 | Chief Financial Officer and Director | 59 | 未披露 | 未持股 | 2026-07-20 |
| Colin A. Doughan | 男 | Chief Executive Officer and Director | 46 | 25.00万美元 | 484.60 | 2026-07-20 |
| Adam Logal | 男 | Director | 47 | 未披露 | 未持股 | 2026-07-20 |
| Phillip Frost | 男 | Director | 89 | 未披露 | 未持股 | 2026-07-20 |
| Jane H. Hsiao | 女 | Chairman of the Board and Chief Executive Officer and Director | 78 | 未披露 | 未持股 | 2026-07-20 |
| Adam Logal | 男 | Director | 48 | 未披露 | 未持股 | 2026-07-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James Martin | 男 | Chief Financial Officer and Director | 59 | 未披露 | 未持股 | 2026-07-20 |
| Michael J. Bowker | 男 | Chief Business Officer | 66 | 8.43万美元 | 10.06 | 2026-07-20 |
| Colin A. Doughan | 男 | Chief Executive Officer and Director | 46 | 25.00万美元 | 484.60 | 2026-07-20 |
| Andrew P. Jones | 男 | Chief Operating Officer | 58 | 25.50万美元 | 9.59 | 2026-07-20 |
| Jane H. Hsiao | 女 | Chairman of the Board and Chief Executive Officer and Director | 78 | 未披露 | 未持股 | 2026-07-20 |
董事简历
中英对照 | 中文 | 英文- James Martin
-
James Martin，2015年3月4日以来，他一直担任首席财务官。此前，他曾担任Vaporin公司的首席财务官（2014年4月以来）。担任Vaporin公司的首席财务官之前，他曾担任Non-Invasive Monitoring Systems公司（NIMS，上市医疗器械公司）的首席财务官（2011年1月以来）。他此前曾担任SafeStitch Medical公司（上市医疗器械公司）的首席财务官（从2011年1月到2013年10月）。从2011年1月到2011年12月，他曾担任Aero Pharmaceuticals公司（私营医药经销商，于2011年12月自愿解散）的财务副总裁。从2010年7月到2011年1月，他曾担任NIMS公司、SafeStitch公司、Aero公司的总会计师。从2008年5月到2010年7月，他曾担任AAR Aircraft Services-Miami公司（ AAR Corp的子公司，一个航空航天和国防公司）的总会计师，在那里他负责所有的财务报表和库存物流。
James Martin has served as Cocrystal Pharma, Inc.'s Chief Financial Officer since June 1, 2017 and as Cocrystal Pharma, Inc.'s Co Chief Executive Officer since May 2021. Prior to that, from February 23, 2017 through May 30, 2017, Mr. Martin served as Cocrystal Pharma, Inc.'s Interim Chief Financial Officer. Mr. Martin has also served as Chief Financial Officer of Non Invasive Monitoring Systems, Inc. (OTC:NIMU) since January 2011. From November 2020 through December 22, 2021, Mr. Martin served on the board of directors and as chair of the audit committee of Big Cypress Acquisition Corp (Nasdaq: BCYPU), a biotechnology focused special purpose acquisition corporation. From February 2017 to November 2020, Mr. Martin served as Chief Financial Officer of Motus GI Holdings, Inc. (Nasdaq:MOTS), a privately held medical device company. From September 2014 to November 2020, Mr. Martin served as Chief Financial Officer of VBI Vaccines Inc. (formerly SciVac Therapeutics, Inc.) (Nasdaq:VBIV), a pharmaceutical development and manufacturing company. Mr. Martin also served as a director of SAB Biotherapeutics, Inc. (Nasdaq: SABS) from November 2020 to October 22, 2021. - James Martin，2015年3月4日以来，他一直担任首席财务官。此前，他曾担任Vaporin公司的首席财务官（2014年4月以来）。担任Vaporin公司的首席财务官之前，他曾担任Non-Invasive Monitoring Systems公司（NIMS，上市医疗器械公司）的首席财务官（2011年1月以来）。他此前曾担任SafeStitch Medical公司（上市医疗器械公司）的首席财务官（从2011年1月到2013年10月）。从2011年1月到2011年12月，他曾担任Aero Pharmaceuticals公司（私营医药经销商，于2011年12月自愿解散）的财务副总裁。从2010年7月到2011年1月，他曾担任NIMS公司、SafeStitch公司、Aero公司的总会计师。从2008年5月到2010年7月，他曾担任AAR Aircraft Services-Miami公司（ AAR Corp的子公司，一个航空航天和国防公司）的总会计师，在那里他负责所有的财务报表和库存物流。
- James Martin has served as Cocrystal Pharma, Inc.'s Chief Financial Officer since June 1, 2017 and as Cocrystal Pharma, Inc.'s Co Chief Executive Officer since May 2021. Prior to that, from February 23, 2017 through May 30, 2017, Mr. Martin served as Cocrystal Pharma, Inc.'s Interim Chief Financial Officer. Mr. Martin has also served as Chief Financial Officer of Non Invasive Monitoring Systems, Inc. (OTC:NIMU) since January 2011. From November 2020 through December 22, 2021, Mr. Martin served on the board of directors and as chair of the audit committee of Big Cypress Acquisition Corp (Nasdaq: BCYPU), a biotechnology focused special purpose acquisition corporation. From February 2017 to November 2020, Mr. Martin served as Chief Financial Officer of Motus GI Holdings, Inc. (Nasdaq:MOTS), a privately held medical device company. From September 2014 to November 2020, Mr. Martin served as Chief Financial Officer of VBI Vaccines Inc. (formerly SciVac Therapeutics, Inc.) (Nasdaq:VBIV), a pharmaceutical development and manufacturing company. Mr. Martin also served as a director of SAB Biotherapeutics, Inc. (Nasdaq: SABS) from November 2020 to October 22, 2021.
- Colin A. Doughan
-
自2022年3月起，Colin A. Doughan担任Gravitics的联合创始人兼首席执行官，Gravitics是一家为商业空间站开发大型模块以支持人类太空和企业服务的公司。从2003年1月到2022年2月，Doughan先生在洛克希德马丁担任高级财务和业务运营经理，负责管理数十亿美元美国政府项目的预算和报告，包括USSTRATCOM的核计划、范登堡的发射场现代化以及空间态势感知卫星星座。从2010年6月到2019年12月，在洛克希德马丁任职的同时，他还是卫星服务公司Altius Space Machines的联合创始人，该公司于2019年被Voyager Space Holdings成功收购。Doughan先生拥有内布拉斯加州大学MBA学位和西北学院管理和市场营销文学学士学位。他持有积极的绝密/SCI许可。
Colin A. Doughan has served as Co Founder and Chief Executive Officer of Gravitics, a company developing large modules to support humans in space and enterprise services for commercial space stations, since March 2022. From January 2003 to February 2022, Mr. Doughan was Senior Finance and Business Operations Manager at Lockheed Martin, where he managed budgets and reporting for multi billion dollar U.S. government programs, including nuclear programs for USSTRATCOM, launch range modernization at Vandenberg, and space situational awareness satellite constellations. From June 2010 to December 2019, concurrent with his role at Lockheed Martin, he was also Co Founder of Altius Space Machines, a satellite servicing company, which was successfully acquired by Voyager Space Holdings in 2019. Mr. Doughan holds an MBA from the University of Nebraska and a Bachelor of Arts in Management and Marketing from Northwestern College. He holds an active Top Secret/SCI clearance. - 自2022年3月起，Colin A. Doughan担任Gravitics的联合创始人兼首席执行官，Gravitics是一家为商业空间站开发大型模块以支持人类太空和企业服务的公司。从2003年1月到2022年2月，Doughan先生在洛克希德马丁担任高级财务和业务运营经理，负责管理数十亿美元美国政府项目的预算和报告，包括USSTRATCOM的核计划、范登堡的发射场现代化以及空间态势感知卫星星座。从2010年6月到2019年12月，在洛克希德马丁任职的同时，他还是卫星服务公司Altius Space Machines的联合创始人，该公司于2019年被Voyager Space Holdings成功收购。Doughan先生拥有内布拉斯加州大学MBA学位和西北学院管理和市场营销文学学士学位。他持有积极的绝密/SCI许可。
- Colin A. Doughan has served as Co Founder and Chief Executive Officer of Gravitics, a company developing large modules to support humans in space and enterprise services for commercial space stations, since March 2022. From January 2003 to February 2022, Mr. Doughan was Senior Finance and Business Operations Manager at Lockheed Martin, where he managed budgets and reporting for multi billion dollar U.S. government programs, including nuclear programs for USSTRATCOM, launch range modernization at Vandenberg, and space situational awareness satellite constellations. From June 2010 to December 2019, concurrent with his role at Lockheed Martin, he was also Co Founder of Altius Space Machines, a satellite servicing company, which was successfully acquired by Voyager Space Holdings in 2019. Mr. Doughan holds an MBA from the University of Nebraska and a Bachelor of Arts in Management and Marketing from Northwestern College. He holds an active Top Secret/SCI clearance.
- Adam Logal
-
Adam Logal于2025年9月3日，公司董事会委任Adam Logal为董事。Logal先生自2014年3月起担任OPKO的高级副总裁、首席财务官、首席会计官、司库，自2012年7月至2014年3月担任财务副总裁、首席会计官、司库，自2007年3月至2012年7月担任财务总监、TERM3、司库。此外，Logal先生还曾在2020年7月至2021年6月期间担任OPKO前子公司GeneDX，LLC的总裁。此前，他曾于2017年至2024年在Xenetics Biosciences，Inc.（NASDAQ：XBIO）董事会任职，于2014年4月至2018年在VBI Vaccines疫苗公司（NASDAQ：VBIV）董事会任职。2002年至2007年，Logal先生在Nabi Biopharmaceuticals的高级管理层任职，该公司是一家上市的生物制药公司，从事专有产品的开发和商业化。Logal先生在Nabi Biopharmaceuticals担任过越来越多的职务，最近担任会计和报告高级总监。
Adam Logal On September 3, 2025, the Company's Board appointed Adam Logal as a director. Mr. Logal has served as OPKO's Senior Vice President, Chief Financial Officer, Chief Accounting Officer, and Treasurer since March 2014, Vice President of Finance, Chief Accounting Officer and Treasurer from July 2012 until March 2014, and Director of Finance, Chief Accounting Officer and Treasurer from March 2007 until July 2012. In addition, Mr. Logal also served as President of GeneDx, LLC, a former subsidiary of OPKO, from July 2020 to June 2021. He previously served on the board of directors of Xenetics Biosciences, Inc. (NASDAQ:XBIO) from 2017 to 2024 and VBI Vaccines, Inc. (NASDAQ:VBIV) from April 2014 until 2018. From 2002 to 2007, Mr. Logal served in senior management of Nabi Biopharmaceuticals, a publicly traded, biopharmaceutical company engaged in the development and commercialization of proprietary products. Mr. Logal held various positions of increasing responsibility at Nabi Biopharmaceuticals, last serving as Senior Director of Accounting and Reporting. - Adam Logal于2025年9月3日，公司董事会委任Adam Logal为董事。Logal先生自2014年3月起担任OPKO的高级副总裁、首席财务官、首席会计官、司库，自2012年7月至2014年3月担任财务副总裁、首席会计官、司库，自2007年3月至2012年7月担任财务总监、TERM3、司库。此外，Logal先生还曾在2020年7月至2021年6月期间担任OPKO前子公司GeneDX，LLC的总裁。此前，他曾于2017年至2024年在Xenetics Biosciences，Inc.（NASDAQ：XBIO）董事会任职，于2014年4月至2018年在VBI Vaccines疫苗公司（NASDAQ：VBIV）董事会任职。2002年至2007年，Logal先生在Nabi Biopharmaceuticals的高级管理层任职，该公司是一家上市的生物制药公司，从事专有产品的开发和商业化。Logal先生在Nabi Biopharmaceuticals担任过越来越多的职务，最近担任会计和报告高级总监。
- Adam Logal On September 3, 2025, the Company's Board appointed Adam Logal as a director. Mr. Logal has served as OPKO's Senior Vice President, Chief Financial Officer, Chief Accounting Officer, and Treasurer since March 2014, Vice President of Finance, Chief Accounting Officer and Treasurer from July 2012 until March 2014, and Director of Finance, Chief Accounting Officer and Treasurer from March 2007 until July 2012. In addition, Mr. Logal also served as President of GeneDx, LLC, a former subsidiary of OPKO, from July 2020 to June 2021. He previously served on the board of directors of Xenetics Biosciences, Inc. (NASDAQ:XBIO) from 2017 to 2024 and VBI Vaccines, Inc. (NASDAQ:VBIV) from April 2014 until 2018. From 2002 to 2007, Mr. Logal served in senior management of Nabi Biopharmaceuticals, a publicly traded, biopharmaceutical company engaged in the development and commercialization of proprietary products. Mr. Logal held various positions of increasing responsibility at Nabi Biopharmaceuticals, last serving as Senior Director of Accounting and Reporting.
- Phillip Frost
-
Phillip Frost，医学博士， 2007年3月以来担任Ladenburg Thalmann Financial Services Inc.公司的CEO和董事会主席。2010年3月，他被任命为Teva Pharmaceutical Industries, Limited, or Teva NYSE：TEVA董事会主席，2006年1月Teva 被IVAX Corporation收购时，他曾担任董事会副主席。他于1987年曾任IVAX公司董事会主席兼首席执行官。1972年至1986年，他担任位于迈阿密的美国西奈山医学中心皮肤科（the Department of Dermatology at Mt. Sinai Medical Center of Greater Miami）主任。他于1972年是Key Pharmaceuticals, Inc.董事会主席，直至该公司在1986年被Schering Plough Corporation收购。他于2006年7月被任命为Ladenburg Thalmann Financial Services Inc. （NYSE MKT：LTS）董事会主席，LTS是一家投资银行、资产管理、证券经纪公司，通过其主要的运营子公司Ladenburg Thalmann & Co . Inc 。 而提供服务。2001年到2002年、以及2004年至今，他是Ladenburg Thalmann董事会成员。他担任迈阿密大学（the University of Miami）理事会、俄罗斯the Skolkovo-Scientific Advisory Council顾问委会、中国上海先进免疫化学研究所（the Shanghai Institute for Advanced Immunochemical Studies in China）、佛罗里达受托委员会（The Florida Council）100名成员之一，并是the Miami Jewish Home for the Aged和西奈山医疗中心（the Mount Sinai Medical Center）理事会成员。他也是高档品牌开发和营销商Castle Brands （NYSE MKT：ROX）董事、开发抗病毒治疗人类疾病的生物科技公司Biozone Pharmaceuticals Inc. （OTCBB： BZNE）、发展阶段医疗设备公司TransEnterix,Inc 。（OTCBB：TRXC）（TRXC开创性的使用灵活的仪器和机器人提高微创手术）等公司的董事。他之前于2013年8月担任Continucare Corporation公司、SafeStitch Medical Inc.公司（并入TransEnterix, Inc.公司之前）、PROLOR Biotech, Inc.公司（被Cocrystal Pharma, Inc.收购之前）的董事，于2012年12月担任美国证交所（现在的纽约证交所MKT）主管人员和联席副主席，并直至2012年11月担任the Scripps Research Institute理事会成员。他已成功建立一些制药公司，并监管大量医药产品的发展和商业化。
Phillip Frost has been a director of Cocrystal since January 2, 2014 and formerly a director of Cocrystal Discovery, Inc., Cocrystal Pharma, Inc.'s subsidiary, from 2008 to 2014. He has served as CEO and Chairman of OPKO Health, Inc. (Nasdaq:OPK) ("OPKO"), a multi national pharmaceutical and diagnostics company since March 2007. He has served as a member of the Board of Trustees of the University of Miami since 1983 and was Chairman from 2001 to 2004. He is on the Advisory Board of the Shanghai Institute for Advanced Immunochemical Studies in China and is a Trustee of each of the Miami Jewish Home for the Aged and the Mount Sinai Medical Center. He serves as Chairman of Temple Emanu El, Governor of Tel Aviv University and is a member of the Executive Committee of The Phillip and Patricia Frost Museum of Science. Dr. Frost served as a director of Ladenburg Thalmann Financial Services Inc. from 2004 to 2006 and as Chairman from July 2006 until September 2018. He previously served as an Expert Member of the Scientific Advisory Council of the Skolkovo Foundation in Russia. Dr. Frost previously served as Vice Chairman of Cogint, Inc., now known as Fluent, Inc. (Nasdaq:FLNT), and as a director for Castle Brands Inc. (NYSE American:ROX). He served as Vice Chair of TEVA and then Chair from 2006 – 2012 after its purchase of IVAX Pharmaceuticals which Dr. Frost founded and where he served as Chairman and CEO. - Phillip Frost，医学博士， 2007年3月以来担任Ladenburg Thalmann Financial Services Inc.公司的CEO和董事会主席。2010年3月，他被任命为Teva Pharmaceutical Industries, Limited, or Teva NYSE：TEVA董事会主席，2006年1月Teva 被IVAX Corporation收购时，他曾担任董事会副主席。他于1987年曾任IVAX公司董事会主席兼首席执行官。1972年至1986年，他担任位于迈阿密的美国西奈山医学中心皮肤科（the Department of Dermatology at Mt. Sinai Medical Center of Greater Miami）主任。他于1972年是Key Pharmaceuticals, Inc.董事会主席，直至该公司在1986年被Schering Plough Corporation收购。他于2006年7月被任命为Ladenburg Thalmann Financial Services Inc. （NYSE MKT：LTS）董事会主席，LTS是一家投资银行、资产管理、证券经纪公司，通过其主要的运营子公司Ladenburg Thalmann & Co . Inc 。 而提供服务。2001年到2002年、以及2004年至今，他是Ladenburg Thalmann董事会成员。他担任迈阿密大学（the University of Miami）理事会、俄罗斯the Skolkovo-Scientific Advisory Council顾问委会、中国上海先进免疫化学研究所（the Shanghai Institute for Advanced Immunochemical Studies in China）、佛罗里达受托委员会（The Florida Council）100名成员之一，并是the Miami Jewish Home for the Aged和西奈山医疗中心（the Mount Sinai Medical Center）理事会成员。他也是高档品牌开发和营销商Castle Brands （NYSE MKT：ROX）董事、开发抗病毒治疗人类疾病的生物科技公司Biozone Pharmaceuticals Inc. （OTCBB： BZNE）、发展阶段医疗设备公司TransEnterix,Inc 。（OTCBB：TRXC）（TRXC开创性的使用灵活的仪器和机器人提高微创手术）等公司的董事。他之前于2013年8月担任Continucare Corporation公司、SafeStitch Medical Inc.公司（并入TransEnterix, Inc.公司之前）、PROLOR Biotech, Inc.公司（被Cocrystal Pharma, Inc.收购之前）的董事，于2012年12月担任美国证交所（现在的纽约证交所MKT）主管人员和联席副主席，并直至2012年11月担任the Scripps Research Institute理事会成员。他已成功建立一些制药公司，并监管大量医药产品的发展和商业化。
- Phillip Frost has been a director of Cocrystal since January 2, 2014 and formerly a director of Cocrystal Discovery, Inc., Cocrystal Pharma, Inc.'s subsidiary, from 2008 to 2014. He has served as CEO and Chairman of OPKO Health, Inc. (Nasdaq:OPK) ("OPKO"), a multi national pharmaceutical and diagnostics company since March 2007. He has served as a member of the Board of Trustees of the University of Miami since 1983 and was Chairman from 2001 to 2004. He is on the Advisory Board of the Shanghai Institute for Advanced Immunochemical Studies in China and is a Trustee of each of the Miami Jewish Home for the Aged and the Mount Sinai Medical Center. He serves as Chairman of Temple Emanu El, Governor of Tel Aviv University and is a member of the Executive Committee of The Phillip and Patricia Frost Museum of Science. Dr. Frost served as a director of Ladenburg Thalmann Financial Services Inc. from 2004 to 2006 and as Chairman from July 2006 until September 2018. He previously served as an Expert Member of the Scientific Advisory Council of the Skolkovo Foundation in Russia. Dr. Frost previously served as Vice Chairman of Cogint, Inc., now known as Fluent, Inc. (Nasdaq:FLNT), and as a director for Castle Brands Inc. (NYSE American:ROX). He served as Vice Chair of TEVA and then Chair from 2006 – 2012 after its purchase of IVAX Pharmaceuticals which Dr. Frost founded and where he served as Chairman and CEO.
- Jane H. Hsiao
-
Jane H. Hsiao， 她是哲学博士，拥有工商管理硕士学位。她曾一直担任公司的副主席兼首席技术官（2007年5月以来）。她曾担任IVAX公司的技术事务副主席（从1995年到2006年1月）。她曾担任IVAX Animal Health公司（IVAX公司的兽医产品子公司）董事长、首席执行官和总裁（从1998年到2006年）。她曾一直担任Non-Invasive Monitoring Systems公司（OTCBB：NIMU）（一个医疗设备公司）的董事会主席（2008年10月以来），并于2012年2月被任命为Non-Invasive Monitoring Systems公司的临时首席执行官。她也是董事，任职于TransEnterix（OTCBB：TRXC）（一个医疗设备公司）、Neovasc公司（TSXV：NVC）（一个公司开发和营销医学专业血管设备）、Biozone Pharmaceuticals公司（OTCBB：BZNE）（生物技术公司开发抗病毒治疗人类疾病）。她此前曾担任Sorrento Therapeutics公司（OTCBB：SRNE）（发展阶段生物制药公司）、PROLOR Biotech公司的董事（2013年8月被公司收购之前）的董事，以及SafeSitch Medical公司（与TransEnterix公司合并之前）的董事会主席。
Jane H. Hsiao,has served as Vice-Chairman and Chief Technical Officer of the Company since May 2007 and as a director since February 2007. Dr. Hsiao has served as Chairman of the Board of Non-Invasive Monitoring Systems, Inc. (OTC US:NIMU), a medical device company, since October 2008 and was named Interim Chief Executive Officer of Non-Invasive Monitoring Systems, Inc. in February 2012. Dr. Hsiao previously served as a director of Cocrystal Pharma, Inc. (NASDAQ GM:COCP), a biotechnology company developing new treatments for viral diseases, Neovasc, Inc. (NASDAQ CM:NVCN), a company developing and marketing medical specialty vascular devices, and Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company. Dr. Hsiao served as the Vice Chairman-Technical Affairs of IVAX from 1995 to January 2006. Dr. Hsiao served as Chairman, Chief Executive Officer and President of IVAX Animal Health, IVAX's veterinary products subsidiary, from 1998 to 2006. - Jane H. Hsiao， 她是哲学博士，拥有工商管理硕士学位。她曾一直担任公司的副主席兼首席技术官（2007年5月以来）。她曾担任IVAX公司的技术事务副主席（从1995年到2006年1月）。她曾担任IVAX Animal Health公司（IVAX公司的兽医产品子公司）董事长、首席执行官和总裁（从1998年到2006年）。她曾一直担任Non-Invasive Monitoring Systems公司（OTCBB：NIMU）（一个医疗设备公司）的董事会主席（2008年10月以来），并于2012年2月被任命为Non-Invasive Monitoring Systems公司的临时首席执行官。她也是董事，任职于TransEnterix（OTCBB：TRXC）（一个医疗设备公司）、Neovasc公司（TSXV：NVC）（一个公司开发和营销医学专业血管设备）、Biozone Pharmaceuticals公司（OTCBB：BZNE）（生物技术公司开发抗病毒治疗人类疾病）。她此前曾担任Sorrento Therapeutics公司（OTCBB：SRNE）（发展阶段生物制药公司）、PROLOR Biotech公司的董事（2013年8月被公司收购之前）的董事，以及SafeSitch Medical公司（与TransEnterix公司合并之前）的董事会主席。
- Jane H. Hsiao,has served as Vice-Chairman and Chief Technical Officer of the Company since May 2007 and as a director since February 2007. Dr. Hsiao has served as Chairman of the Board of Non-Invasive Monitoring Systems, Inc. (OTC US:NIMU), a medical device company, since October 2008 and was named Interim Chief Executive Officer of Non-Invasive Monitoring Systems, Inc. in February 2012. Dr. Hsiao previously served as a director of Cocrystal Pharma, Inc. (NASDAQ GM:COCP), a biotechnology company developing new treatments for viral diseases, Neovasc, Inc. (NASDAQ CM:NVCN), a company developing and marketing medical specialty vascular devices, and Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company. Dr. Hsiao served as the Vice Chairman-Technical Affairs of IVAX from 1995 to January 2006. Dr. Hsiao served as Chairman, Chief Executive Officer and President of IVAX Animal Health, IVAX's veterinary products subsidiary, from 1998 to 2006.
- Adam Logal
-
Adam Logal ，他担任OPKO公司的副总裁和首席财务官（2014年4月以来），以及OPKO公司的财务副总裁、首席财务官和司库（2007年3月以来）。从2002年到2007年，他担任Nabi Biopharmaceuticals公司（公开交易，生物制药公司，从事自营产品的开发和商业化）的高级管理人员。他曾任职Nabi Biopharmaceuticals公司，并不断被提拔，最终担任高级主管，负责会计和报告。
Adam Logal,has served as OPKO's Senior Vice President, Chief Financial Officer, Chief Accounting Officer, and Treasurer since March 2014, Vice President of Finance, Chief Accounting Officer and Treasurer from July 2012 until March 2014, and Director of Finance, Chief Accounting Officer and Treasurer from March 2007 until July 2012. In addition, Mr. Logal also served as President of GeneDx, a subsidiary of OPKO, from July 2020 to June 2021. He currently serves as chairman of the board of directors of Xenetics Biosciences, Inc. (NASDAQ CM:XBIO), a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics. He previously served on the board of directors of VBI Vaccines, Inc. (NASDAQ:VBIV) from April 2014 until 2018. From 2002 to 2007, Mr. Logal served in senior management of Nabi Biopharmaceuticals, a publicly traded, biopharmaceutical company engaged in the development and commercialization of proprietary products. Mr. Logal held various positions of increasing responsibility at Nabi Biopharmaceuticals, last serving as Senior Director of Accounting and Reporting. - Adam Logal ，他担任OPKO公司的副总裁和首席财务官（2014年4月以来），以及OPKO公司的财务副总裁、首席财务官和司库（2007年3月以来）。从2002年到2007年，他担任Nabi Biopharmaceuticals公司（公开交易，生物制药公司，从事自营产品的开发和商业化）的高级管理人员。他曾任职Nabi Biopharmaceuticals公司，并不断被提拔，最终担任高级主管，负责会计和报告。
- Adam Logal,has served as OPKO's Senior Vice President, Chief Financial Officer, Chief Accounting Officer, and Treasurer since March 2014, Vice President of Finance, Chief Accounting Officer and Treasurer from July 2012 until March 2014, and Director of Finance, Chief Accounting Officer and Treasurer from March 2007 until July 2012. In addition, Mr. Logal also served as President of GeneDx, a subsidiary of OPKO, from July 2020 to June 2021. He currently serves as chairman of the board of directors of Xenetics Biosciences, Inc. (NASDAQ CM:XBIO), a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics. He previously served on the board of directors of VBI Vaccines, Inc. (NASDAQ:VBIV) from April 2014 until 2018. From 2002 to 2007, Mr. Logal served in senior management of Nabi Biopharmaceuticals, a publicly traded, biopharmaceutical company engaged in the development and commercialization of proprietary products. Mr. Logal held various positions of increasing responsibility at Nabi Biopharmaceuticals, last serving as Senior Director of Accounting and Reporting.
高管简历
中英对照 | 中文 | 英文- James Martin
James Martin，2015年3月4日以来，他一直担任首席财务官。此前，他曾担任Vaporin公司的首席财务官（2014年4月以来）。担任Vaporin公司的首席财务官之前，他曾担任Non-Invasive Monitoring Systems公司（NIMS，上市医疗器械公司）的首席财务官（2011年1月以来）。他此前曾担任SafeStitch Medical公司（上市医疗器械公司）的首席财务官（从2011年1月到2013年10月）。从2011年1月到2011年12月，他曾担任Aero Pharmaceuticals公司（私营医药经销商，于2011年12月自愿解散）的财务副总裁。从2010年7月到2011年1月，他曾担任NIMS公司、SafeStitch公司、Aero公司的总会计师。从2008年5月到2010年7月，他曾担任AAR Aircraft Services-Miami公司（ AAR Corp的子公司，一个航空航天和国防公司）的总会计师，在那里他负责所有的财务报表和库存物流。
James Martin has served as Cocrystal Pharma, Inc.'s Chief Financial Officer since June 1, 2017 and as Cocrystal Pharma, Inc.'s Co Chief Executive Officer since May 2021. Prior to that, from February 23, 2017 through May 30, 2017, Mr. Martin served as Cocrystal Pharma, Inc.'s Interim Chief Financial Officer. Mr. Martin has also served as Chief Financial Officer of Non Invasive Monitoring Systems, Inc. (OTC:NIMU) since January 2011. From November 2020 through December 22, 2021, Mr. Martin served on the board of directors and as chair of the audit committee of Big Cypress Acquisition Corp (Nasdaq: BCYPU), a biotechnology focused special purpose acquisition corporation. From February 2017 to November 2020, Mr. Martin served as Chief Financial Officer of Motus GI Holdings, Inc. (Nasdaq:MOTS), a privately held medical device company. From September 2014 to November 2020, Mr. Martin served as Chief Financial Officer of VBI Vaccines Inc. (formerly SciVac Therapeutics, Inc.) (Nasdaq:VBIV), a pharmaceutical development and manufacturing company. Mr. Martin also served as a director of SAB Biotherapeutics, Inc. (Nasdaq: SABS) from November 2020 to October 22, 2021.- James Martin，2015年3月4日以来，他一直担任首席财务官。此前，他曾担任Vaporin公司的首席财务官（2014年4月以来）。担任Vaporin公司的首席财务官之前，他曾担任Non-Invasive Monitoring Systems公司（NIMS，上市医疗器械公司）的首席财务官（2011年1月以来）。他此前曾担任SafeStitch Medical公司（上市医疗器械公司）的首席财务官（从2011年1月到2013年10月）。从2011年1月到2011年12月，他曾担任Aero Pharmaceuticals公司（私营医药经销商，于2011年12月自愿解散）的财务副总裁。从2010年7月到2011年1月，他曾担任NIMS公司、SafeStitch公司、Aero公司的总会计师。从2008年5月到2010年7月，他曾担任AAR Aircraft Services-Miami公司（ AAR Corp的子公司，一个航空航天和国防公司）的总会计师，在那里他负责所有的财务报表和库存物流。
- James Martin has served as Cocrystal Pharma, Inc.'s Chief Financial Officer since June 1, 2017 and as Cocrystal Pharma, Inc.'s Co Chief Executive Officer since May 2021. Prior to that, from February 23, 2017 through May 30, 2017, Mr. Martin served as Cocrystal Pharma, Inc.'s Interim Chief Financial Officer. Mr. Martin has also served as Chief Financial Officer of Non Invasive Monitoring Systems, Inc. (OTC:NIMU) since January 2011. From November 2020 through December 22, 2021, Mr. Martin served on the board of directors and as chair of the audit committee of Big Cypress Acquisition Corp (Nasdaq: BCYPU), a biotechnology focused special purpose acquisition corporation. From February 2017 to November 2020, Mr. Martin served as Chief Financial Officer of Motus GI Holdings, Inc. (Nasdaq:MOTS), a privately held medical device company. From September 2014 to November 2020, Mr. Martin served as Chief Financial Officer of VBI Vaccines Inc. (formerly SciVac Therapeutics, Inc.) (Nasdaq:VBIV), a pharmaceutical development and manufacturing company. Mr. Martin also served as a director of SAB Biotherapeutics, Inc. (Nasdaq: SABS) from November 2020 to October 22, 2021.
- Michael J. Bowker
Michael J. Bowker自2023年10月起担任位于圣地亚哥的航空航天公司Voyager Space Technology Systems的副总裁兼业务经理，负责开发、捕获和管理公司的业务账簿。2020年6月至2023年10月，他担任Voyager Space Holdings，Inc.业务发展副总裁，领导公司及其投资组合公司的业务发展战略。在此之前，2019年10月至2020年8月，他担任Altius Space Machines，Inc.的首席营收和运营官以及董事会成员，Altius Space Machines，Inc.是一家被Voyager Space Holdings收购的卫星服务公司。Bowker先生拥有佛罗里达理工学院海洋工程理学学士学位。
Michael J. Bowker has served as Vice President and Business Manager of Voyager Space Technology Systems, a San Diego based aerospace company, since October 2023, where he is responsible for developing, capturing, and managing the company's book of business. From June 2020 to October 2023, he was Vice President of Business Development at Voyager Space Holdings, Inc., leading business development strategy across the company and its portfolio companies. Prior to that, from October 2019 to August 2020, he was Chief Revenue and Operating Officer and a member of the Board of Directors of Altius Space Machines, Inc., a satellite servicing company that was acquired by Voyager Space Holdings. Mr. Bowker holds a Bachelor of Science in Ocean Engineering from the Florida Institute of Technology.- Michael J. Bowker自2023年10月起担任位于圣地亚哥的航空航天公司Voyager Space Technology Systems的副总裁兼业务经理，负责开发、捕获和管理公司的业务账簿。2020年6月至2023年10月，他担任Voyager Space Holdings，Inc.业务发展副总裁，领导公司及其投资组合公司的业务发展战略。在此之前，2019年10月至2020年8月，他担任Altius Space Machines，Inc.的首席营收和运营官以及董事会成员，Altius Space Machines，Inc.是一家被Voyager Space Holdings收购的卫星服务公司。Bowker先生拥有佛罗里达理工学院海洋工程理学学士学位。
- Michael J. Bowker has served as Vice President and Business Manager of Voyager Space Technology Systems, a San Diego based aerospace company, since October 2023, where he is responsible for developing, capturing, and managing the company's book of business. From June 2020 to October 2023, he was Vice President of Business Development at Voyager Space Holdings, Inc., leading business development strategy across the company and its portfolio companies. Prior to that, from October 2019 to August 2020, he was Chief Revenue and Operating Officer and a member of the Board of Directors of Altius Space Machines, Inc., a satellite servicing company that was acquired by Voyager Space Holdings. Mr. Bowker holds a Bachelor of Science in Ocean Engineering from the Florida Institute of Technology.
- Colin A. Doughan
自2022年3月起，Colin A. Doughan担任Gravitics的联合创始人兼首席执行官，Gravitics是一家为商业空间站开发大型模块以支持人类太空和企业服务的公司。从2003年1月到2022年2月，Doughan先生在洛克希德马丁担任高级财务和业务运营经理，负责管理数十亿美元美国政府项目的预算和报告，包括USSTRATCOM的核计划、范登堡的发射场现代化以及空间态势感知卫星星座。从2010年6月到2019年12月，在洛克希德马丁任职的同时，他还是卫星服务公司Altius Space Machines的联合创始人，该公司于2019年被Voyager Space Holdings成功收购。Doughan先生拥有内布拉斯加州大学MBA学位和西北学院管理和市场营销文学学士学位。他持有积极的绝密/SCI许可。
Colin A. Doughan has served as Co Founder and Chief Executive Officer of Gravitics, a company developing large modules to support humans in space and enterprise services for commercial space stations, since March 2022. From January 2003 to February 2022, Mr. Doughan was Senior Finance and Business Operations Manager at Lockheed Martin, where he managed budgets and reporting for multi billion dollar U.S. government programs, including nuclear programs for USSTRATCOM, launch range modernization at Vandenberg, and space situational awareness satellite constellations. From June 2010 to December 2019, concurrent with his role at Lockheed Martin, he was also Co Founder of Altius Space Machines, a satellite servicing company, which was successfully acquired by Voyager Space Holdings in 2019. Mr. Doughan holds an MBA from the University of Nebraska and a Bachelor of Arts in Management and Marketing from Northwestern College. He holds an active Top Secret/SCI clearance.- 自2022年3月起，Colin A. Doughan担任Gravitics的联合创始人兼首席执行官，Gravitics是一家为商业空间站开发大型模块以支持人类太空和企业服务的公司。从2003年1月到2022年2月，Doughan先生在洛克希德马丁担任高级财务和业务运营经理，负责管理数十亿美元美国政府项目的预算和报告，包括USSTRATCOM的核计划、范登堡的发射场现代化以及空间态势感知卫星星座。从2010年6月到2019年12月，在洛克希德马丁任职的同时，他还是卫星服务公司Altius Space Machines的联合创始人，该公司于2019年被Voyager Space Holdings成功收购。Doughan先生拥有内布拉斯加州大学MBA学位和西北学院管理和市场营销文学学士学位。他持有积极的绝密/SCI许可。
- Colin A. Doughan has served as Co Founder and Chief Executive Officer of Gravitics, a company developing large modules to support humans in space and enterprise services for commercial space stations, since March 2022. From January 2003 to February 2022, Mr. Doughan was Senior Finance and Business Operations Manager at Lockheed Martin, where he managed budgets and reporting for multi billion dollar U.S. government programs, including nuclear programs for USSTRATCOM, launch range modernization at Vandenberg, and space situational awareness satellite constellations. From June 2010 to December 2019, concurrent with his role at Lockheed Martin, he was also Co Founder of Altius Space Machines, a satellite servicing company, which was successfully acquired by Voyager Space Holdings in 2019. Mr. Doughan holds an MBA from the University of Nebraska and a Bachelor of Arts in Management and Marketing from Northwestern College. He holds an active Top Secret/SCI clearance.
- Andrew P. Jones
自2024年6月起，Andrew P. Jones担任设计和制造大型加压空间站和货运模块的航空航天公司Gravitics的物流产品副总裁。2024年3月至2024年6月，他是一家空间技术提供商的业务顾问，就项目管理、工程和供应链战略提供建议。2021年3月至2024年3月，他担任Landers and Spacecraft（Programs，Engineering and Manufacturing）董事，并曾担任太空机器人公司Astrobotic Technology，Inc.的董事会成员，负责月球着陆器和卫星项目的损益。在此之前，2018年7月至2020年12月，他在商业载人航天公司飞船公司（维珍银河）担任工程总监（从2019年11月起，兼任项目经理）。琼斯先生拥有英国卡迪夫大学学院机械工程和能源研究学士学位。
Andrew P. Jones has served as Vice President, Logistic Products of Gravitics, an aerospace company designing and manufacturing large pressurized space station and cargo modules, since June 2024. From March 2024 to June 2024, he was a Business Consultant to a space technology provider, advising on program management, engineering, and supply chain strategy. From March 2021 to March 2024, he was Director of Landers and Spacecraft (Programs, Engineering and Manufacturing) and a former member of the Board of Directors at Astrobotic Technology, Inc., a space robotics company, where he held P&L responsibility for lunar lander and satellite programs. Prior to that, from July 2018 to December 2020, he was Director of Engineering (and, from November 2019, also Program Manager) at The Spaceship Company (Virgin Galactic), a commercial human spaceflight company. Mr. Jones holds a BEng in Mechanical Engineering and Energy Studies from University College Cardiff UK.- 自2024年6月起，Andrew P. Jones担任设计和制造大型加压空间站和货运模块的航空航天公司Gravitics的物流产品副总裁。2024年3月至2024年6月，他是一家空间技术提供商的业务顾问，就项目管理、工程和供应链战略提供建议。2021年3月至2024年3月，他担任Landers and Spacecraft（Programs，Engineering and Manufacturing）董事，并曾担任太空机器人公司Astrobotic Technology，Inc.的董事会成员，负责月球着陆器和卫星项目的损益。在此之前，2018年7月至2020年12月，他在商业载人航天公司飞船公司（维珍银河）担任工程总监（从2019年11月起，兼任项目经理）。琼斯先生拥有英国卡迪夫大学学院机械工程和能源研究学士学位。
- Andrew P. Jones has served as Vice President, Logistic Products of Gravitics, an aerospace company designing and manufacturing large pressurized space station and cargo modules, since June 2024. From March 2024 to June 2024, he was a Business Consultant to a space technology provider, advising on program management, engineering, and supply chain strategy. From March 2021 to March 2024, he was Director of Landers and Spacecraft (Programs, Engineering and Manufacturing) and a former member of the Board of Directors at Astrobotic Technology, Inc., a space robotics company, where he held P&L responsibility for lunar lander and satellite programs. Prior to that, from July 2018 to December 2020, he was Director of Engineering (and, from November 2019, also Program Manager) at The Spaceship Company (Virgin Galactic), a commercial human spaceflight company. Mr. Jones holds a BEng in Mechanical Engineering and Energy Studies from University College Cardiff UK.
- Jane H. Hsiao
Jane H. Hsiao， 她是哲学博士，拥有工商管理硕士学位。她曾一直担任公司的副主席兼首席技术官（2007年5月以来）。她曾担任IVAX公司的技术事务副主席（从1995年到2006年1月）。她曾担任IVAX Animal Health公司（IVAX公司的兽医产品子公司）董事长、首席执行官和总裁（从1998年到2006年）。她曾一直担任Non-Invasive Monitoring Systems公司（OTCBB：NIMU）（一个医疗设备公司）的董事会主席（2008年10月以来），并于2012年2月被任命为Non-Invasive Monitoring Systems公司的临时首席执行官。她也是董事，任职于TransEnterix（OTCBB：TRXC）（一个医疗设备公司）、Neovasc公司（TSXV：NVC）（一个公司开发和营销医学专业血管设备）、Biozone Pharmaceuticals公司（OTCBB：BZNE）（生物技术公司开发抗病毒治疗人类疾病）。她此前曾担任Sorrento Therapeutics公司（OTCBB：SRNE）（发展阶段生物制药公司）、PROLOR Biotech公司的董事（2013年8月被公司收购之前）的董事，以及SafeSitch Medical公司（与TransEnterix公司合并之前）的董事会主席。
Jane H. Hsiao,has served as Vice-Chairman and Chief Technical Officer of the Company since May 2007 and as a director since February 2007. Dr. Hsiao has served as Chairman of the Board of Non-Invasive Monitoring Systems, Inc. (OTC US:NIMU), a medical device company, since October 2008 and was named Interim Chief Executive Officer of Non-Invasive Monitoring Systems, Inc. in February 2012. Dr. Hsiao previously served as a director of Cocrystal Pharma, Inc. (NASDAQ GM:COCP), a biotechnology company developing new treatments for viral diseases, Neovasc, Inc. (NASDAQ CM:NVCN), a company developing and marketing medical specialty vascular devices, and Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company. Dr. Hsiao served as the Vice Chairman-Technical Affairs of IVAX from 1995 to January 2006. Dr. Hsiao served as Chairman, Chief Executive Officer and President of IVAX Animal Health, IVAX's veterinary products subsidiary, from 1998 to 2006.- Jane H. Hsiao， 她是哲学博士，拥有工商管理硕士学位。她曾一直担任公司的副主席兼首席技术官（2007年5月以来）。她曾担任IVAX公司的技术事务副主席（从1995年到2006年1月）。她曾担任IVAX Animal Health公司（IVAX公司的兽医产品子公司）董事长、首席执行官和总裁（从1998年到2006年）。她曾一直担任Non-Invasive Monitoring Systems公司（OTCBB：NIMU）（一个医疗设备公司）的董事会主席（2008年10月以来），并于2012年2月被任命为Non-Invasive Monitoring Systems公司的临时首席执行官。她也是董事，任职于TransEnterix（OTCBB：TRXC）（一个医疗设备公司）、Neovasc公司（TSXV：NVC）（一个公司开发和营销医学专业血管设备）、Biozone Pharmaceuticals公司（OTCBB：BZNE）（生物技术公司开发抗病毒治疗人类疾病）。她此前曾担任Sorrento Therapeutics公司（OTCBB：SRNE）（发展阶段生物制药公司）、PROLOR Biotech公司的董事（2013年8月被公司收购之前）的董事，以及SafeSitch Medical公司（与TransEnterix公司合并之前）的董事会主席。
- Jane H. Hsiao,has served as Vice-Chairman and Chief Technical Officer of the Company since May 2007 and as a director since February 2007. Dr. Hsiao has served as Chairman of the Board of Non-Invasive Monitoring Systems, Inc. (OTC US:NIMU), a medical device company, since October 2008 and was named Interim Chief Executive Officer of Non-Invasive Monitoring Systems, Inc. in February 2012. Dr. Hsiao previously served as a director of Cocrystal Pharma, Inc. (NASDAQ GM:COCP), a biotechnology company developing new treatments for viral diseases, Neovasc, Inc. (NASDAQ CM:NVCN), a company developing and marketing medical specialty vascular devices, and Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company. Dr. Hsiao served as the Vice Chairman-Technical Affairs of IVAX from 1995 to January 2006. Dr. Hsiao served as Chairman, Chief Executive Officer and President of IVAX Animal Health, IVAX's veterinary products subsidiary, from 1998 to 2006.